JNJ

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?
Motley Fool
Fri, 11/17/23 - 09:59 am
JNJ
Intuitive Surgical
Medtech
robotic surgery
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Thu, 11/16/23 - 11:45 am
Astellas
Propella Therapeutics
M&A
JNJ
Zytiga
prostate cancer
J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses
Fierce Pharma
Tue, 11/14/23 - 09:56 pm
JNJ
Bayer
Xarelto
blood thinners
AHA
peripheral artery disease
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Biopharma Reporter
Thu, 11/9/23 - 09:55 am
Janssen
JNJ
rheumatoid arthritis
nipocalimab
clinical trials
J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina
Fierce Pharma
Wed, 11/8/23 - 09:57 pm
JNJ
Janssen
Fujifilm Diosynth Biotechnologies
CDMOs
North Carolina
J&J targets 2024 for Ottava FDA filing
Medtech Dive
Tue, 11/7/23 - 11:05 pm
JNJ
Medtech
Ottava
robotic surgery
HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations
BioSpace
Tue, 11/7/23 - 09:48 am
JNJ
Stelara
HHS
Inflation Reduction Act
Medicare
drug pricing
Study of Johnson & Johnson device shows promising results for AFib
Clinical Trials Arena
Fri, 11/3/23 - 10:54 am
JNJ
Medtech
QDOT MICRO
atrial fibrillation
Amgen scores FDA approval for Stelara biosimilar
Pharmaceutical Technology
Wed, 11/1/23 - 10:16 pm
Amgen
Stelara
biosimilars
JNJ
FDA
Wezlana
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
Reuters
Tue, 10/31/23 - 10:18 am
GSK
JNJ
hepatitis B
JNJ-3989
Janssen
Cidara’s J&J-partnered immunotherapy could target flu and cancer
Pharma Voice
Thu, 10/26/23 - 10:35 am
Cidara
JNJ
immunotherapy
drug-Fc conjugates
cancer
Flu
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
Tue, 10/24/23 - 10:21 am
JNJ
Janssen
Rybrevant
clinical trials
non-small cell lung cancer
J&J bites back against dengue, linking antiviral to protection from infection in challenge trial
Fierce Biotech
Fri, 10/20/23 - 10:15 am
JNJ
dengue
JNJ-1802
antiviral
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
Fri, 10/20/23 - 10:05 am
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?
Medical Marketing and Media
Thu, 10/19/23 - 11:29 am
JNJ
Rybrevant
AstraZeneca
Tagrisso
EGFR-mutated NSCLC
After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti
Fierce Pharma
Wed, 10/18/23 - 07:44 pm
JNJ
Legend Biotech
Multiple Myeloma
CAR-T
Carvykti
cell therapy
Why Johnson & Johnson Stock Flopped Today
Motley Fool
Wed, 10/18/23 - 07:39 pm
JNJ
earnings
analysts
J&J Signals Exit from Less Profitable Orthopedic Markets
Medical Devices and Diagnostics Industry
Wed, 10/18/23 - 10:14 am
JNJ
Medtech
Orthopedics
J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance
BioSpace
Tue, 10/17/23 - 09:39 pm
JNJ
earnings
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Clinical Trials Arena
Tue, 10/17/23 - 11:45 am
JNJ
Janssen
clinical trials
Crohn's Disease
Tremfya

Pages